Object

The conception of individual patient-adjusted treatment strategies is constantly emerging in the field of neuro-oncology. Systemic laboratory markers may allow insights into individual needs and estimated treatment benefit at an earliest possible stage. Therefore, the present study was aimed at analyzing the prognostic significance of preoperative routine laboratory values in patients with newly-diagnosed glioblastoma.

Methods

Between 2014 and 2019, 257 patients were surgically treated for newly-diagnosed glioblastoma at the Neuro-Oncology Center of the University Hospital Bonn. Preoperative routine laboratory values including red blood cell distribution width (RDW) and platelet count were reviewed. RDW to platelet count ratio (RPR) was calculated and correlated to overall survival (OS) rates.

Results

Median preoperative RPR was 0.053 (IQR 0.044–0.062). The receiver operating characteristic (ROC) curve indicated an optimal cut-off value for RPR to be 0.05 (AUC 0.62; p = 0.002, 95% CI 0.544–0.685). 101 patients (39%) presented with a preoperative RPR < 0.05, whereas 156 patients (61%) had a RPR ≥ 0.05. Patients with preoperative RPR < 0.05 exhibited a median OS of 20 months (95% CI 17.9–22.1), which was significantly higher compared to a median OS of 13 months (95% CI 10.9–15.1) in patients with preoperative RPR ≥ 0.05 (p < 0.001).

Conclusions

The present study suggests the RPR to constitute a novel prognostic inflammatory marker for glioblastoma patients in the course of preoperative routine laboratory examinations and might contribute to a personalized medicine approach.

中文翻译：

---

红细胞分布宽度与血小板比率证实了新诊断胶质母细胞瘤患者的术前生存预测

目的

个体患者调整治疗策略的概念在神经肿瘤学领域不断涌现。全身性实验室标志物可以让人们尽早了解个体需求和估计的治疗益处。因此，本研究旨在分析术前常规实验室检查值对新诊断胶质母细胞瘤患者的预后意义。

方法

2014 年至 2019 年间，257 名患者在波恩大学医院神经肿瘤中心接受了新诊断的胶质母细胞瘤的手术治疗。回顾了术前常规实验室值，包括红细胞分布宽度（RDW）和血小板计数。计算 RDW 与血小板计数比 (RPR) 并与总生存率 (OS) 相关。

结果

术前 RPR 中位数为 0.053（IQR 0.044-0.062）。受试者工作特征 (ROC) 曲线表明 RPR 的最佳截止值为 0.05 (AUC 0.62; p = 0.002, 95% CI 0.544–0.685)。101 名患者 (39%) 的术前 RPR < 0.05，而 156 名患者 (61%) 的 RPR ≥ 0.05。术前 RPR < 0.05 的患者的中位 OS 为 20 个月（95% CI 17.9-22.1），与术前 RPR ≥ 0.05 的患者的中位 OS 13 个月（95% CI 10.9-15.1）相比显着更高（ p < 0.001)。

结论

本研究表明，RPR 在术前常规实验室检查过程中构成胶质母细胞瘤患者的一种新的预后炎症标志物，并可能有助于个性化医疗方法。